Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

T. C. Chang, H. S. Shiah, C. H. Yang, K. H. Yeh, A. L. Cheng, B. N. Shen, Y. W. Wang, C. G. Yeh, N. J. Chiang, J. Y. Chang, L. T. Chen

研究成果: 雜誌貢獻文章

47 引文 (Scopus)

摘要

Purpose: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. Results: A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and 180 mg/m2 (four patients). DLT was observed in three patients, one at 120 mg/m2 (grade 3 catheter-related infection) and two at 180 mg/m2 (grade 4 neutropenia lasting for >3 days in one, grade 4 hematological toxicities and grade 4 diarrhea in the other). MTD was determined as 120 mg/m2. Comparing with those after free-form irinotecan in the literature, the dose-normalized PK of SN-38 (the active metabolite) after PEP02 was characterized by lower C max, prolonged terminal half-life and higher AUC but with significant inter-individual variation. One patient who died of treatment-related toxicity had significantly higher C max and AUC levels of SN-38 than those of the other three patients at 180 mg/m2. Post hoc pharmacogenetic study showed that the patient had a combined heterozygosity genotype of UGT1A1∗6/∗28. Two patients had objective tumor response. Conclusions: PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation. The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies.
原文英語
頁(從 - 到)579-586
頁數8
期刊Cancer Chemotherapy and Pharmacology
75
發行號3
DOIs
出版狀態已發佈 - 一月 1 2015

指紋

irinotecan
Tumors
Pharmacokinetics
Toxicity
Neoplasms
Maximum Tolerated Dose
Liposomes
Catheters
Metabolites
Area Under Curve
Encapsulation
Refractory materials

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

引用此文

Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. / Chang, T. C.; Shiah, H. S.; Yang, C. H.; Yeh, K. H.; Cheng, A. L.; Shen, B. N.; Wang, Y. W.; Yeh, C. G.; Chiang, N. J.; Chang, J. Y.; Chen, L. T.

於: Cancer Chemotherapy and Pharmacology, 卷 75, 編號 3, 01.01.2015, p. 579-586.

研究成果: 雜誌貢獻文章

Chang, TC, Shiah, HS, Yang, CH, Yeh, KH, Cheng, AL, Shen, BN, Wang, YW, Yeh, CG, Chiang, NJ, Chang, JY & Chen, LT 2015, 'Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients', Cancer Chemotherapy and Pharmacology, 卷 75, 編號 3, 頁 579-586. https://doi.org/10.1007/s00280-014-2671-x
Chang, T. C. ; Shiah, H. S. ; Yang, C. H. ; Yeh, K. H. ; Cheng, A. L. ; Shen, B. N. ; Wang, Y. W. ; Yeh, C. G. ; Chiang, N. J. ; Chang, J. Y. ; Chen, L. T. / Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. 於: Cancer Chemotherapy and Pharmacology. 2015 ; 卷 75, 編號 3. 頁 579-586.
@article{27d3d4d50ae548f194be25af16aebb91,
title = "Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients",
abstract = "Purpose: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. Results: A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and 180 mg/m2 (four patients). DLT was observed in three patients, one at 120 mg/m2 (grade 3 catheter-related infection) and two at 180 mg/m2 (grade 4 neutropenia lasting for >3 days in one, grade 4 hematological toxicities and grade 4 diarrhea in the other). MTD was determined as 120 mg/m2. Comparing with those after free-form irinotecan in the literature, the dose-normalized PK of SN-38 (the active metabolite) after PEP02 was characterized by lower C max, prolonged terminal half-life and higher AUC but with significant inter-individual variation. One patient who died of treatment-related toxicity had significantly higher C max and AUC levels of SN-38 than those of the other three patients at 180 mg/m2. Post hoc pharmacogenetic study showed that the patient had a combined heterozygosity genotype of UGT1A1∗6/∗28. Two patients had objective tumor response. Conclusions: PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation. The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies.",
keywords = "Irinotecan sucrosofate, Liposome, MM-398, PEP02, Pharmacokinetics, UGT1A1 gene",
author = "Chang, {T. C.} and Shiah, {H. S.} and Yang, {C. H.} and Yeh, {K. H.} and Cheng, {A. L.} and Shen, {B. N.} and Wang, {Y. W.} and Yeh, {C. G.} and Chiang, {N. J.} and Chang, {J. Y.} and Chen, {L. T.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00280-014-2671-x",
language = "English",
volume = "75",
pages = "579--586",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

AU - Chang, T. C.

AU - Shiah, H. S.

AU - Yang, C. H.

AU - Yeh, K. H.

AU - Cheng, A. L.

AU - Shen, B. N.

AU - Wang, Y. W.

AU - Yeh, C. G.

AU - Chiang, N. J.

AU - Chang, J. Y.

AU - Chen, L. T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. Results: A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and 180 mg/m2 (four patients). DLT was observed in three patients, one at 120 mg/m2 (grade 3 catheter-related infection) and two at 180 mg/m2 (grade 4 neutropenia lasting for >3 days in one, grade 4 hematological toxicities and grade 4 diarrhea in the other). MTD was determined as 120 mg/m2. Comparing with those after free-form irinotecan in the literature, the dose-normalized PK of SN-38 (the active metabolite) after PEP02 was characterized by lower C max, prolonged terminal half-life and higher AUC but with significant inter-individual variation. One patient who died of treatment-related toxicity had significantly higher C max and AUC levels of SN-38 than those of the other three patients at 180 mg/m2. Post hoc pharmacogenetic study showed that the patient had a combined heterozygosity genotype of UGT1A1∗6/∗28. Two patients had objective tumor response. Conclusions: PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation. The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies.

AB - Purpose: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. Results: A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and 180 mg/m2 (four patients). DLT was observed in three patients, one at 120 mg/m2 (grade 3 catheter-related infection) and two at 180 mg/m2 (grade 4 neutropenia lasting for >3 days in one, grade 4 hematological toxicities and grade 4 diarrhea in the other). MTD was determined as 120 mg/m2. Comparing with those after free-form irinotecan in the literature, the dose-normalized PK of SN-38 (the active metabolite) after PEP02 was characterized by lower C max, prolonged terminal half-life and higher AUC but with significant inter-individual variation. One patient who died of treatment-related toxicity had significantly higher C max and AUC levels of SN-38 than those of the other three patients at 180 mg/m2. Post hoc pharmacogenetic study showed that the patient had a combined heterozygosity genotype of UGT1A1∗6/∗28. Two patients had objective tumor response. Conclusions: PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation. The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies.

KW - Irinotecan sucrosofate

KW - Liposome

KW - MM-398

KW - PEP02

KW - Pharmacokinetics

KW - UGT1A1 gene

UR - http://www.scopus.com/inward/record.url?scp=84923651982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923651982&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2671-x

DO - 10.1007/s00280-014-2671-x

M3 - Article

C2 - 25577133

AN - SCOPUS:84923651982

VL - 75

SP - 579

EP - 586

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -